APA (7th ed.) Citation

Tunitsky-Lifshitz, Y., Maoz-Segal, R., Niznik, S., Shavit, R., Yahia, S. H., Langevitz, P., & Agmon-Levin, N. (2023). The third dose of BNT162b2 COVID-19 vaccine is efficacious and safe for systemic lupus erythematosus patients receiving belimumab. Lupus, 32(5), 675. https://doi.org/10.1177/09612033231164262

Chicago Style (17th ed.) Citation

Tunitsky-Lifshitz, Yulia, Ramit Maoz-Segal, Stanley Niznik, Ronen Shavit, Soad Haj Yahia, Pnina Langevitz, and Nancy Agmon-Levin. "The Third Dose of BNT162b2 COVID-19 Vaccine Is Efficacious and Safe for Systemic Lupus Erythematosus Patients Receiving Belimumab." Lupus 32, no. 5 (2023): 675. https://doi.org/10.1177/09612033231164262.

MLA (9th ed.) Citation

Tunitsky-Lifshitz, Yulia, et al. "The Third Dose of BNT162b2 COVID-19 Vaccine Is Efficacious and Safe for Systemic Lupus Erythematosus Patients Receiving Belimumab." Lupus, vol. 32, no. 5, 2023, p. 675, https://doi.org/10.1177/09612033231164262.